Indian Journal of Cancer
Home  ICS  Feedback Subscribe Top cited articles Login 
Users Online :948
Small font sizeDefault font sizeIncrease font size
Navigate Here
 »   Next article
 »   Previous article
 »   Table of Contents

Resource Links
 »   Similar in PUBMED
 »  Search Pubmed for
 »  Search in Google Scholar for
 »Related articles
 »   Citation Manager
 »   Access Statistics
 »   Reader Comments
 »   Email Alert *
 »   Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed10368    
    Printed294    
    Emailed5    
    PDF Downloaded739    
    Comments [Add]    
    Cited by others 4    

Recommend this journal

 

 REVIEW ARTICLE
Year : 2010  |  Volume : 47  |  Issue : 4  |  Page : 443-451

Biological response modifiers: Current use and future prospects in cancer therapy


1 Department of Pharmacology, Himalayan Institute of Medical Sciences, HIHT University Jolly grant, Doiwala, Dehradun, Uttarakhand – 248 140, India
2 Department of E.N.T, Himalayan Institute of Medical Sciences, HIHT University Jolly grant, Doiwala, Dehradun, Uttarakhand - 248 140, India

Correspondence Address:
M Bisht
Department of E.N.T, Himalayan Institute of Medical Sciences, HIHT University Jolly grant, Doiwala, Dehradun, Uttarakhand - 248 140
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0019-509X.73559

Rights and Permissions

Over the past few decades, considerable success has been achieved in the field of cancer treatment with biological response modifiers (BRM), which are agents that improve the body's ability to fight cancer by immunostimulation. Biological agents, such as interferons and interleukins, provide nonspecific active immunity, whereas the monoclonal antibodies provide passive immunity. Apart from this, other biological agents, such as antiangiogenic agents, matrix metalloprotease inhibitors, tyrosine kinase inhibitors, and tumor vaccines, are also increasingly being used in cancer treatment. Hematopoietic factors, such as granulocyte colony-stimulating factor, are used to increase the general immunity and prevent opportunistic infection. BRM are basically used alone or as adjuvants to cancer chemotherapeutic agents. This review sheds light on the current use and the future development of cancer immunotherapy. Search strategy included Pubmed, using the terms "Biological response modifiers in cancer" citations relevant to the topic were screened.






[FULL TEXT] [PDF]*


        
Print this article     Email this article

  Site Map | What's new | Copyright and Disclaimer
  Online since 1st April '07
  © 2007 - Indian Journal of Cancer | Published by Wolters Kluwer - Medknow